The federal government scrapped a plan to have health insurance companies fund coverage of obesity drugs for seniors, opting instead to pay for the medicine with taxpayer dollars through the ...

Some health insurers are pushing back against a new program that will allow Medicare beneficiaries to pay $50 per month for ...

Two of the biggest insurance providers have expressed reluctance to participate in the government’s BALANCE program that ...

Meanwhile — in a late-breaking moment — federal officials are having to pivot on the fly after insurers panned the effort to ...

The Trump administration is delaying a voluntary model that aimed to expand access to GLP-1s in Part D after pushback from ...

Eli Lilly (LLY) stock and Novo Nordisk (NONOF) stock are in focus as Medicare extends interim coverage for GLP-1 weight loss ...

The Trump administration is delaying a pilot program where Medicare would cover the costs of GLP-1 weight-loss drugs, ...

Insurance coverage for GLP-1 medications like Ozempic and Wegovy varies widely depending on the condition and your plan.

By adding digital health and nutrition support to Rx access, the retailer hopes to win share with the weight-loss army.

Retailers race into GLP-1 market as Amazon and Walmart expand weight management programs, reshaping access and care delivery in obesity treatment.

UnitedHealth Group Inc. sees difficulties with the Trump administration’s plan to cover obesity drugs in Medicare next year, ...

Health insurers are raising questions about the Trump administration’s plan to cover obesity drugs in Medicare next year, casting doubt on whether enough insurers will sign on to the effort for it to ...